Sandoz

R&D

Eloise McLennan interview with Peter Stenico

Reuters Pharma Europe 2024 – Peter Stenico

Pioneering access to biosimilars is crucial for strengthening health equity by providing affordable, life-changing therapies to patients worldwide.

News

Sandoz gets first FDA OK for denosumab biosimilars

Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US

News

Sandoz will pay $265m to settle price fixing case in US

Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind

News

Sandoz makes its first post-spinout acquisition

Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in

News

AbbVie hit as CVS says it will cut Humira from formularies

CVS Health has said it will remove AbbVie’s big-selling immunology drug Humira from most of its national formulary lists of reimbursable products, and offer biosimilar ver

News